Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Reports summarize cancer vaccines research from F.X. Ding and co-authors
June 16th, 2009
"To develop a hepatitis B virus (HBV) therapeutic vaccine that can induce a broad but specific immune response and significant antitumor effects both in vivo and in vitro, we inserted HBV X protein (HBx)-derived epitopes HBX(52-60), HBx((92-100)), and HBx((115-123)); a novel subdominant cytolytic T lymphocyte (CTL) epitope HBx((140-148)); and the universal T helper epitope pan human leukocyte antigen DR-binding epitope into HBV core protein to form multiepitope peptide-loaded virus-like particles (VLPs)," researchers in Shanghai, People's Republic of China report. "CTL responses against epitope-loaded VLPs were elicited by priming with VLP-pulsed dendritic cells in both...
Source: Cancer Weekly (2009-06-16)
|
